Search results
Tematy dnia
3 cze 2021 · Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.
- Genetic Finding Can Guide Immunotherapy for Prostate Cancer
This study was supported by Challenge and Young Investigator...
- Targets a Protein Called PSMA
Prostate cancer treatment took a major step forward today as...
- Finding Hidden Cancer Cells
A 65-year-old textile designer living in New York City’s...
- Lisa Bodei
Memorial Sloan Kettering's doctors and scientists are...
- Michael J. Morris, MD
A Phase I Study of JNJ-69086420 for Advanced Prostate Cancer...
- Research
Memorial Sloan Kettering's doctors and scientists are...
- Genetic Finding Can Guide Immunotherapy for Prostate Cancer
23 mar 2022 · Prostate cancer treatment took a major step forward today as the U.S. Food and Drug Administration approved a new therapy that zeros in on cancer cells to destroy them. The treatment, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface called PSMA (prostate-specific ...
25 paź 2024 · Tufts Medicine brings a next-generation treatment for advanced prostate cancer that offers new hope for patients whose cancer has spread and no longer responds to hormone therapy or docetaxel chemotherapy.
12 lip 2023 · In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
12 cze 2024 · But results from a first in-human Phase I trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, showed that patients with advanced prostate...
26 sty 2021 · In a large clinical trial, the drug, relugolix (Orgovyx), was shown to be more effective at reducing testosterone levels in men with advanced prostate cancer than another commonly used treatment, leuprolide (Lupron).
5 sty 2024 · With the expanded approval of enzalutamide (Xtandi), oncologists have a new treatment option to offer some patients with prostate cancer who have had a biochemical recurrence.
